Category: Research

Diamyd_logo

FDA Grants Diamyd Medical´s Diamyd Orphan Drug Designation

Diamyd Medical announced the Food and Drug Administration (FDA) granted its type 1 diabetes drug candidate Diamyd® Orphan Drug Designation. Orphan drugs qualify for several incentives including a seven-year period of market exclusivity in the US...
0 Shares
Amylin logo

Amylin and Takeda Advance Development of New Obesity Treatment

Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited announced that following positive phase 2 study results in a new obesity treatment, they will advance towards phase 3 development of a combination treatment for obesity which includes pramlintide (an analog of the natural hormone amylin) and metreleptin (an analog of the natural hormone leptin)...
0 Shares

Study Shows Vinegar Reduces Blood Glucose Levels

A new study shows vinegar reduces post-meal hyperglycemia in type 1 diabetics. While previous studies have shown that vinegar improves insulin sensitivity in healthy or insulin-resistant subjects, information on the effect of vinegar in type 1 diabetes has been absent....
0 Shares

Mechanism Leading to Diabetic Blindness Identified

Diabetic retinopathy is a common side effect of diabetes and the leading cause of blindness in young adults in the United States. Scientists have long known that high blood sugar levels damage blood vessels in the eye, but they didn't know why or how this happens. Now a Michigan State University scientist has...
0 Shares
osiris-therapeutics-logo

Osiris Completes Enrollment in Stem Cell Trial for Type 1 Diabetes

Osiris Therapeutics, Inc. today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for completing enrollment in a Phase II clinical trial evaluating Prochymal, an adult mesenchymal stem cell therapy, as a treatment for patients recently diagnosed with type 1 diabetes. The milestone is the fourth in a series of payments resulting from JDRF's partnership with Osiris.
0 Shares
FDA

FDA Clears Clibra’s Insulin Patch

Calibra Medical Inc., formerly known as Seattle Medical Technologies Inc., announced today that the U.S. Food and Drug Administration has given Finesse, the company’s insulin patch-pen, 510(k) clearance. Only 2” long, 1” wide and ¼” thick, Finesse is able to hold and deliver prescribed amounts of insulin over multiple days while...
0 Shares
JDRF New Logo

JDRF Announces Diabetes Research Program with Johnson & Johnson

The Juvenile Diabetes Research Foundation announced today in a press release that it will begin working with The Johnson & Johnson Corporate Office of Science and Technology, and its affiliates, to speed the development of drug targets and pathways to promote the survival and function of insulin-producing cells in people who have diabetes...
0 Shares
Diamyd_logo

FDA Approves Diamyd Vaccine Study In Children As Young As 3

Diamyd Medical, a Swedish diabetes company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications, reports today that the US FDA has approved the experimental use of Diamyd® vaccine in children as young as 3 years of age in the TrialNet GAD study, enrolling 126 new onset type 1 diabetes patients in North America...
0 Shares